Tracer library / [225Ac]Ac-PSMA-I&T

Structure of PSMA-I&T (unlabelled parent compound, from PubChem) — Unlabelled parent compoundPubChem CID 156596528

[225Ac]Ac-PSMA-I&T

Also written as PSMA I&T; [Ac-225]Ac-PSMA-I&T; PSMA-I&T

Radionuclide: Ac-225 t½ 14284.8 min
Modality: Therapy
Production route: —
Stage: Clinical research
Syntheses indexed: 4

Prostate cancer Dosimetry and biodistribution studies Radiochemistry methodology PSMA-directed radioligand therapy

What it is

Compound class: PSMA-targeting peptide (urea-based ligand), DOTA-conjugated, radiolabeled with Ac-225
Target / mechanism: Targets prostate-specific membrane antigen (PSMA) PMID 41043997
Clinical application: Targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC) PMID 34068206
Theranostic pair: [68Ga]Ga-PSMA-I&T

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Modular-Lab EAZY Eckert & Ziegler	vendor cassette	SPE	80-90%	>95%	PSMA-I&T piCHEM, Raaba-Grambach, Austria	34358076 2021 Pharmaceuticals (Basel) the Modular-Lab EAZY (ML EAZY), Eckert & Ziegler - final radiochemical yields of 80–90% for the 225Ac-labeled peptides
Manual synthesis	—	—	—	—	PSMA I&T piCHEM, Raaba-Grambach, Austria	42481872 2026 EJNMMI Radiopharm Chem a solid 225Ac sample (40–60 MBq) was dissolved within 30 min by using 30 µL of 0.1 M HCl at room temperature
Modular-Lab EAZY Eckert & Ziegler	vendor cassette	SPE	80-90%	>95%	PSMA-I&T piCHEM, Raaba-Grambach, Austria	34358076 2021 Pharmaceuticals (Basel) The Modular-Lab EAZY module (GTL) with software Modular-Lab v6.2 was obtained from Eckert & Ziegler (Berlin, Germany). - final radiochemical yields of 80–90% for the 225Ac-labeled peptides
Manual synthesis Biotage	custom manifold	SPE	>95%	>90%	PSMA-I&T Scintomics, Fürstenfeldbruck, Germany	34068206 2021 Pharmaceutics a specific microwave (Biotage Initiator+, Biotage, Uppsala, Sweden) was used for labeling - radiochemical yield >95%

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

First Clinical Results for PSMA-Targeted α-Therapy Using 225Ac-PSMA-I&T in Advanced-mCRPC Patients.
2021 · J Nucl Med · Retrospective
Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging.
2023 · Eur J Nucl Med Mol Imaging · Clinical study

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: Scintomics, Fürstenfeldbruck, piCHEM
Typical final purification: —

Need this precursor?We can point you to suppliers for [225Ac]Ac-PSMA-I&T, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 5 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68. Compound class inferred from precursor name (not stated outright) -- PMID 34358076: 'PSMA-I&T'. Stage set/updated at stage 23 from PMID 34068206: 'The start of the phase I dose escalation study is planned in the near future.'. | Stage 30 (2026-09-18): Stage was 'phase I clinical trial (planned/dose escalation)'; normalised to 'Clinical research', original wording kept here.